MONTREAL, Canada--(BUSINESS WIRE)--Afferent Pharmaceuticals, a clinical-stage biopharmaceutical company developing first-in-class, small molecules that target P2X3 receptors, today announced preclinical in vivo results demonstrating that an investigational P2X3 receptor antagonist significantly prevented and reversed bone cancer pain behavior in comparison to vehicle controls. These data expand on earlier findings and reveal that a marked reduction in apparent bone cancer pain occurs following oral administration of the proprietary P2X3 antagonist. Results from the study were presented in a poster session at the 13th World Congress on Pain in Montreal, Canada.
